Russian antitumor drugs first time received a registration certificate in Europe
Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration was received with the support of ICM d.o.o partner and is valid for 5 years. The first deliveries shall start in June 2020. Registration processes started in December 2018. During this time, a thorough examination of the drugs documentary and samples quality was carried out. According to the law, the first commercial series of the drug for sale is…
You might be interested in
